BTKi modulate the TME and tumor B-cell interaction, leading to a redistribution of lymphocytosis caused by inhibition of signaling and function of chemokine receptors (CXCR4, CXCR5) and adhesion molecules. Here, CXCR5 is linked to neoplasm.